

## DORSET MEDICINES ADVISORY GROUP Recommendation Summary

Formerly the Bournemouth, Dorset and Poole Health Technologies Forum, DMAG represents the four provider Trusts and GPs within the Clinical Commissioning Group (CCG). It provides recommendations to the CCG on the prescribing and commissioning of medicines.

Summary of recommendations considered at a meeting of the group on 27<sup>th</sup> September 2016. Formulary entries and associated documents can be accessed at [www.dorsetformulary.nhs.uk](http://www.dorsetformulary.nhs.uk).

PRODUCT	DECISION	COMMENTS
<b>1. Products re-categorised</b>		
Betamethasone (soluble tablets)	Re-categorised to <b>Green</b>	Betamethasone soluble tablets re-categorised from Red to Green , as to align with other oral corticosteroids
Warticon®	Re-categorised to <b>Green</b>	For use by healthcare professionals in primary care appropriately trained in the diagnosis and management of anogenital warts (e.g. a STIF course or clinical attachment to a GUM clinic)” was approved.
<b>2. New requests</b>		
Oralieve® oral gel	Approved	Oralieve® oral gel to be included on the pan Dorset Formulary as <b>Green</b> classification.
Rasagiline	Approved	Rasagiline to be included on the pan Dorset Formulary as <b>Amber</b> with Shared Care Guideline

PRODUCT	DECISION	COMMENTS
<b>3. Products considered by NICE</b>		
Commissioning statement on the use of SGLT2s in combination therapy	Approved	The statement has been updated to include reference to NICE NG18 which states that an SGLT2 can be considered as part of a first or second intensification when certain criteria are met.
Commissioning statement for Degarelix (Firmagon®)	Approved	The statement commissions in accordance with NICE TA 404 the use of Degarelix (Firmagon®) for advanced hormone-dependent prostate cancer in adults with spinal metastases with a <b>Red</b> classification
<b>4. Miscellaneous recommendations by DMAG</b>		
Position Statement on the Prescribing of Preservative Free Eye Drops	Approved	Now available on the CCG website and pan Dorset Formulary
Dry Eye Guidance	Approval Pending	Will be available on the CCG Website and pan Dorset Formulary once finalised
Eye Drop Table – Brand conversion to Generic	Approved	Now available on the CCG website and pan Dorset Formulary
Shared Care Guidelines for Riluzole in the management of Motor Neurone Disease (MND) specifically Amyotrophic lateral Sclerosis (ALS)	Approved	Now available on the CCG website and pan Dorset Formulary
Shared Care Guidelines for prescribing Rasagiline in Parkinson's Disease	Approved	Now available on the CCG website and pan Dorset Formulary
Shared Care Guidelines for the use of Buccal Midazolam in Adults	Approval Pending	Will be available on the CCG Website and pan Dorset Formulary once finalised
Shared Care Guidelines for Prescribing Atypical Antipsychotics in Adults and Older Persons in Schizophrenia and Related Psychoses	Approved	Now available on the CCG website and pan Dorset Formulary

PRODUCT	DECISION	COMMENTS
Urinary Continence Preferred Product List	Approved	The existing list has been reviewed and the new list will be launched by the Continence Service in February The new list is available on the CCG website and pan Dorset Formulary

Classification of products:

'RED' drugs for hospital use only

'AMBER with shared care' drugs suitable for use with shared care arrangements

'AMBER' drugs suitable for use without shared care arrangements

'GREEN' drugs suitable for prescribing in primary and secondary care

'Not Recommended' – drugs not recommended for use in Dorset

The new traffic light system can be found on the Dorset CCG internet at: [Dorset CCG - Traffic light scheme](#)